A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2019-11, Vol.94 (11), p.E291-E294
Hauptverfasser:	Tomlinson, Benjamin K., Tuscano, Joseph M., Abedi, Mehrdad, Welborn, Jeanna, Arora, Mili, O'Donnell, Robert T., Wun, Ted, Jonas, Brian A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Doxorubicin Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Febrile Neutropenia - chemically induced Female Hematology Humans Hydroxyurea - administration & dosage Kaplan-Meier Estimate Leukemia, Myeloid, Acute - drug therapy Male Middle Aged Myeloid leukemia Neoplastic Cells, Circulating Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Progression-Free Survival Proteasome Inhibitors - administration & dosage Proteasome Inhibitors - adverse effects Targeted cancer therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!